Terumo Cardiovascular Receives FDA Clearance for CDI OneView™ Monitoring System

Terumo Cardiovascular has received US FDA 510(k) clearance for the CDI OneView Monitoring System, which provides visibility into key patient parameters during cardiopulmonary bypass surgery that are critical to perfusion safety and improved patient outcomes.

The new CDI OneView system measures up to 22 key parameters, including flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), area under the DO2 curve (AUC) and arterial oxygen saturation (SaO2). This innovative system offers maximum configurability and flexibility in how parameters are displayed and prioritised to best suit clinical needs and preferences, while still providing the critical information clinicians rely on.

With the launch of the new CDI OneView system, Terumo Cardiovascular continues to bring value and improved patient care to healthcare providers and critically ill cardiac patients,” said Robert DeRyke, President and CEO of Terumo Cardiovascular, the subsidiary of Japan’s Terumo Corporation focused exclusively on cardiovascular surgical specialties.


en_GBEnglish (UK)